Orexigen Insists It Can Grow Contrave After Takeda Exit
This article was originally published in The Pink Sheet Daily
Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.
You may also be interested in...
Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.
Referencing opioids and suicidal thoughts is not sufficient, US regulators say; letter comes as Orexigen has seen an upsurge in Contrave prescriptions.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.